Gyre Share Price

Gyre Share Price

NASDAQ: GYRE | Small Cap | Healthcare
$4.21
-$0.29 (-6.44%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Gyre Stock Performance

Open
$4.42
Prev. Close
$4.50
Circuit Range
N/A
Day Range
$4.13 - $4.42
Year Range
$4.00 - $8.96
Volume
10,709
Average Traded
$4.23

Gyre Share Price Today

As of 21 November 2026, Gyre Therapeutics, Inc.'s share price is $4.21. The stock opened at $4.42, compared to its previous close of $4.50. During today's trading session, Gyre Therapeutics, Inc.'s share price traded between $4.13 and $4.42, with an average price of $4.28. Over the past 52 weeks, the stock has recorded a high of $8.96 and a low of $4.00. In terms of performance, Gyre Therapeutics, Inc.'s share price has declined by 28.58% over the last six months and is down 45.47% on a year-on-year basis.

Gyre Share Price Chart

Line chart of the Gyre price trend over the selected period. The price fell overall, ranging from 4.13 to 4.49, ending at 4.21.
$4.13$4.42
L
Show Current Price
H

Gyre Stock Fundamentals & Key Indicators

Market Cap
$376.14M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.24
Revenue (TTM)
$116.59B
Return On Equity (TTM)
-24.20%
Profit Margin
4.31%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-422.99%

Gyre Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$30.56$37.20$22.52$29.11
Net Profit$3.61-$1.72-$8.69-$11.66
Net Profit Margin11.81%-4.62%-38.59%-40.05%
Income ChangeN/A-147.65%-405.23%-34.18%

Gyre Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$113.45$105.76$116.59
Net Profit-$92.93$12.09$5.03
Net Profit Margin-81.91%11.43%4.31%
Income ChangeN/A113.01%-58.40%

Gyre Balance Sheet

All figures in USD Million

Particulars202520242023
Non Current Assets70.460.6259.32
Current Assets149.3664.7957.22
Total Assets219.76125.41116.54
Non Current Liabilities7.627.4918.02
Current Liabilities23.7819.5220.05
Total Liabilities31.427.038.07
Shareholders' Equity59.5598.413.95

Gyre Cash Flow

Annually

All figures in USD Million

Particulars202520242023
Operating1.01-3.6425.89
Investing-0.47-19.88-19.76
Financing24.382.12.5

Corporate Actions

Dividend
Ex-date: 13 Jan 2023

Split
Ex-date: 13 Jan 2023

Dividend
Ex-date: 21 Sep 2022

About Gyre

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Gyre Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$4.85
$4.23
-7.44%
Oct 2026
$7.31
$4.57
-37.78%
Sep 2026
$6.40
$7.34
+9.63%
Aug 2026
$5.93
$6.70
+16.42%
Jul 2026
$6.52
$5.75
-12.54%
Jun 2026
$5.92
$6.58
+11.62%
May 2026
$7.80
$5.89
-22.94%
Apr 2026
$7.19
$7.65
+9.91%
Mar 2026
$8.21
$6.96
-15.64%
Feb 2026
$8.00
$8.25
+1.85%
Jan 2026
$6.93
$8.10
+15.06%
Dec 2025
$7.77
$7.04
-8.81%

Gyre Share Price FAQs